NASDAQ:CUR - Neuralstem Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.51 -0.09 (-15.05 %) (As of 03/25/2019 04:00 PM ET)Previous Close$0.5991Today's Range$0.48 - $0.6052-Week Range$0.25 - $2.05Volume362,946 shsAverage Volume291,751 shsMarket Capitalization$9.25 millionP/E RatioN/ADividend YieldN/ABeta2.62 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland. Receive CUR News and Ratings via Email Sign-up to receive the latest news and ratings for CUR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CUR Previous Symbol CUSIPN/A CIK1357459 Webwww.neuralstem.com Phone301-366-4841Debt Debt-to-Equity RatioN/A Current Ratio5.51 Quick Ratio5.51Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$260,000.00 Price / Sales35.57 Cash FlowN/A Price / Cash FlowN/A Book Value$0.56 per share Price / Book0.91Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-4,930,000.00 Net Margins-1,879.39% Return on Equity-85.83% Return on Assets-51.85%Miscellaneous Employees5 Outstanding Shares18,200,000Market Cap$9.25 million Next Earnings Date5/21/2019 (Estimated) OptionableOptionable Neuralstem (NASDAQ:CUR) Frequently Asked Questions What is Neuralstem's stock symbol? Neuralstem trades on the NASDAQ under the ticker symbol "CUR." How were Neuralstem's earnings last quarter? Neuralstem, Inc. (NASDAQ:CUR) announced its quarterly earnings results on Wednesday, November, 14th. The company reported ($0.12) earnings per share for the quarter. Neuralstem had a negative net margin of 1,879.39% and a negative return on equity of 85.83%. View Neuralstem's Earnings History. When is Neuralstem's next earnings date? Neuralstem is scheduled to release their next quarterly earnings announcement on Tuesday, May 21st 2019. View Earnings Estimates for Neuralstem. Has Neuralstem been receiving favorable news coverage? News headlines about CUR stock have trended positive on Monday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Neuralstem earned a daily sentiment score of 2.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an impact on the stock's share price in the near future. Who are some of Neuralstem's key competitors? Some companies that are related to Neuralstem include TRACON Pharmaceuticals (TCON), BIONDVAX PHARMA/S (BVXV), Microbot Medical (MBOT), Vical (VICL), CytRx (CYTR), Titan Pharmaceuticals (TTNP), Windtree Therapeutics (WINT), aTyr Pharma (LIFE), Vaxart (VXRT), TrovaGene (TROV), Aevi Genomic Medicine (GNMX), Genetic Technologies (GENE), Mymetics (MYMX), Enzon Pharmaceuticals (ENZN) and Mateon Therapeutics (MATN). What other stocks do shareholders of Neuralstem own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neuralstem investors own include XOMA (XOMA), MannKind (MNKD), Cytokinetics (CYTK), Novavax (NVAX), Caladrius Biosciences (CLBS), Pluristem Therapeutics (PSTI), SLS International (SLS), TransEnterix (TRXC), Microbot Medical (MBOT) and Athersys (ATHX). Who are Neuralstem's key executives? Neuralstem's management team includes the folowing people: Dr. Kenneth C. Carter, CEO & Exec. Chairman (Age 59)Dr. Karl Y. Johe, Co-Founder & Chief Scientific Officer (Age 59)Dr. Thomas G. Hazel Ph.D., Sr. VP of ResearchDr. David P. Recker, Chief Medical Officer (Age 61) How do I buy shares of Neuralstem? Shares of CUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Neuralstem's stock price today? One share of CUR stock can currently be purchased for approximately $0.51. How big of a company is Neuralstem? Neuralstem has a market capitalization of $9.28 million and generates $260,000.00 in revenue each year. Neuralstem employs 5 workers across the globe. What is Neuralstem's official website? The official website for Neuralstem is http://www.neuralstem.com. How can I contact Neuralstem? Neuralstem's mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The company can be reached via phone at 301-366-4841 or via email at [email protected] MarketBeat Community Rating for Neuralstem (NASDAQ CUR)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 239 (Vote Outperform)Underperform Votes: 214 (Vote Underperform)Total Votes: 453MarketBeat's community ratings are surveys of what our community members think about Neuralstem and other stocks. Vote "Outperform" if you believe CUR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CUR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/25/2019 by MarketBeat.com StaffFeatured Article: How Do Mutual Funds Work?